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Abstract
Background: Based on changes in pharmacokinetics and –dynamics in elderly patients, there are potentially
inappropriate medications (PIM) that should be avoided in patients aged ≥ 65 years. Current studies showed
prescription rates of PIM between 22.5 and 28.4 % in the primary care setting. The evidence concerning
reasons for PIM prescription by FPs is limited.
Methods: This mixed method study consisted of three research parts: 1) semi-standardized content analysis of patients’
records, 2) qualitative interviews with FPs using a) open questions and b) selected patient-specific case vignettes and 3)
qualitative interviews with FPs’ medical assistants. The integration of qualitative interviews was used to explain the
quantitative results (triangulation design). PIM were identified according to the German PRISCUS list. Descriptive and
multivariate statistical analysis was done using SPSS 22.0. Qualitative content analysis of interviews was used to classify the
content of the interviews for indicating pertinent categories. All data were pseudonymously recorded and analyzed.
Results: Content analysis of 1846 patients’ records and interviews with 7 related FPs were conducted. Elderly
patients [n = 1241, mean age: 76, females: 56.6 %] were characterized in average by 8.3 documented chronic
diagnosis. 23.9 % of elderly patients received at least one PIM prescription. Sedatives/hypnotics were the most
frequent prescribed PIM-drugs (13.7 %). Mental disorders, gender and number of long-term medication were
detected as predictors for the probability of a PIM prescription. Common reported reasons for PIM prescription by FPs
concerned limited knowledge regarding PIM, limited applicability of PIM lists in daily practice, lack of time, having no
alternatives in medication, stronger patient-related factors than age that influence prescription, own bad experiences
regarding changes of medication or refusal of following prescriptions of sedative/hypnotics.
Conclusions: It is essential to see FPs in a complex decision making situation with several influencing factors on their
prescribing, including: patient-oriented prioritization, FPs’ experiences in daily practice, FPs’ knowledge regarding
existing recommendations and their trust in it and organizational characteristics of FPs’ daily medical practice. These
pros and cons of PIM prescription in elderly patients should be considered in FPs’ advanced training.
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Background
The discussion of challenges in medical care for elderly
patients (65 years and older) is focused on multimorbid-
ity and polypharmacy. Regarding age-related changes in
pharmacokinetics and -dynamics, the elderly patients’
renal metabolism and clearance as well as first-pass ef-
fect in the liver are delayed in time. This causes different
actions of drug in geriatric vs. younger patients because
the pharmaceutical drugs remain longer in the metabolic
system of the elderly [1].
Prescription of medical drugs in geriatric patients has to
consider these effects. But mostly there is no evidence re-
garding effect of drugs in the elderly. Clinical trials for
testing efficacy of drugs often exclude older patients based
on an upper-age limit, comorbid disease, reduced life ex-
pectancy, physical or mental impairments or use of drugs
aiming to minimize biases on outcomes of the study. But
the results of efficacy studies that exclude older patients
do rarely fit patients in daily medical practice [2, 3].
Common empirical data show higher hospital admis-
sion rates in elderly patients because of adverse drug re-
actions or drug-drug reactions [4–6]. Regarding this and
the complexity of problems with medication for the eld-
erly, expert groups in several countries have developed
so called black lists of drugs for elderly patients, describ-
ing potentially inappropriate medication (PIM).
Due to different formalities and drug markets, country
specific PIM lists are necessary [7]. These country-specific
lists include drugs that are associated with higher risks of
intolerance, adverse drug reaction/events or drug-disease
interactions in elderly patients [8–14].
In Germany the first black list ‘PRISCUS’ (PRerequISites
for a new health Care model for elderly people with mUl-
tiple morbiditieS) was consensually developed in 2010 by
an expert group of geriatrics, pharmacologists and family
practitioners. PRISCUS currently includes 83 drugs that
should be avoided or prescribed at a lower dose in elderly
patients. These recommendations are listed with expert
statements offering alternatives. In case of unavoidability
of PIM prescriptions, recommendations for drug monitor-
ing are given [15].
Rates of PIM prescriptions range worldwide between 12
and 65 % depending on the setting and the used screening
tool. A systematic review determined a median PIM pre-
scription rate of 20.5 % (interquartile range 18.1 to 25.6 %)
in the primary care setting between 1950 and 2011. The
review included 19 studies of 11 different countries that
examined PIM almost by Beers criteria [16]. Current stud-
ies examining older patient samples (mean age > 80 years)
showed prescription rates between 22.5 and 28.4 % in the
primary care setting [17, 18].
Since these rates seem to be high, it would be useful to
understand the prescribing of PIM by family practitioners
(FP) to generate feasible and need-oriented solutions for
improvement of medical care in the elderly. In this con-
text, more evidence is needed regarding FPs’ knowledge of
PIM as well as associated recommendations and their ac-
ceptance and implementation in daily practice.
There is evidence that polypharmacy increases the risk
of PIM in elderly patients [6, 18, 19]. Furthermore, there
are indications that FPs’ knowledge of prescribing for
the elderly is partly insufficient (more frequently in older
FPs) whereas they report a high self-rated confidence in
prescribing [20]. Reported main barriers for appropriate
prescribing seem to be related to FPs’ lack of education
regarding PIM, to organizational characteristics (i.e. lack
of time, limited answer options on insurance formular-
ies, communication difficulties with other doctors) and
to patients (large number of medications, unknown
medications, costs). These findings are based on two
smaller studies using a validated survey instrument to
examine FPs’ knowledge of prescribing for the elderly.
Appropriateness was assessed by standardized case vi-
gnettes [20, 21].
Based on the limited knowledge concerning reasons
for PIM prescription by FPs we examined reasons for
PIM prescription a) in general and b) using real individ-
ual case vignettes of FPs that were detected beforehand
through record analysis. Aims of this analysis were
1) to give an overview of rates of PIM prescription in our
study sample of elderly multimorbid patients with
polymedication in the outpatient primary care setting,
2) to explain influencing factors on prescription of PIM,
3) to examine knowledge and application of PRISCUS
and
4) to understand FPs’ reasons for prescription of PIM.
Methods
Our study was coordinated at the Department of Gen-
eral Practice of the Technische Universität (TU) Dresden
and took place from March 2013 to June 2014. The
study was conducted in cooperation with the Depart-
ment of Health Care Management and Public Health/
Schumpeter School of Business and Economics at the
University of Wuppertal.
Study design
The study was designed as a mixed methods study con-
sisting of three research parts:
(1) semi-standardized content analysis of patients’
records regarding morbidity, drug prescriptions,
admissions/referrals to specialist,
(2) qualitative interviews with FPs that focused on
challenges and barriers in daily medical care of
patients with multimorbidity and polypharmacy
using a) open questions to explore these issues in
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general and b) selected patient-specific case vi-
gnettes for each FP based on results of [1] regarding
comparable topics (PIM: prescription of hypnotics;
medication change; intersectoral cooperation with
in- and out-patient specialists), and
(3) qualitative interviews with their medical assistants
to explore their point of view regarding
organization-related barriers, challenges and room
for improvement for medical care of patients with
multimorbidity and polypharmacy [22].
Results of qualitative interviews with FP and their
medical assistants were used to help explain the quanti-
tative results (triangulation design [23]). More detailed
information on our study design, setting and research in-
struments are already published elsewhere [24].
This publication focuses on results of subanalysis of
research parts (1) and (2) regarding the prescription of
PIM by FPs.
Inclusion of study participants
All 33 FPs from academic teaching practices of the De-
partment of General Practice of TU Dresden situated in
Dresden were invited for participation in the study. After
confirmation of participation by the FPs, all chronic pa-
tients of each participating practice were invited for par-
ticipation if they met following inclusion criteria: a) at
least two parallel chronic diseases and b) two prescribed
long-term medications at least 6 months before 2012.
Furthermore, all medical assistants of the participating
FPs were asked to participate in qualitative interviews.
Data collection
Patients’ records [1] were analyzed from March 2013 to
May 2014 by our project assistants at FPs’ practices
using a semi-standardized entry mask in SPSS 22.0. Pa-
tient records of a randomized quarter of the year 2012
were retrospectively analyzed per patient, and informa-
tion regarding morbidity, admissions/referrals to special-
ists and non-drug and drug prescriptions (including
documented adverse events) were documented. Prescrip-
tions by specialists were only included if FPs had docu-
mented them in the patient records based on the
findings reports sent by the specialists or direct informa-
tion by the patients.
The quarters were assigned randomly to each patient.
Qualitative face-to-face interviews [2] were conducted
by 2 experienced interviewers (scientific project staff )
with 7 FPs around 2–3 weeks after finishing record ana-
lysis. Interviews took place in FPs’ practices and each
interview lasted between 40 and 60 min. Confronting
FPs with their real-life decisions in individual case vi-
gnettes that were chosen from analyzed patients’ records
(see Table 1) we asked them
 to explain their case-related decisions of the pre-
scription of a PIM substance and influencing factors
on it for the respective case vignette,
 to discuss reasons for prescription of PIM in
contrast to known recommendations generally and
 to assess their knowledge, usage and acceptance of
recommendations in daily practice (German
PRISCUS-list).
We used these real-life case vignettes to get more au-
thentic answers by FPs and as concrete starting points
for reflection of the PIM-topic in general. One patient
(>65 years) with the most prescription of benzodiazepine
receptor agonists (so called Z-drugs) not corresponding
to recommendations of PRISCUS per each FP was se-
lected for the respective case vignette (see Table 1).
Analysis
Statistical analysis of data based on record analysis [1] were
done using SPSS 22.0 to describe characteristics of the sam-
ple of patients > 65 years and especially of the subsample af-
fected by PIM prescription. Screening all documented
prescribed drugs, PIM were identified according to the Ger-
man PRISCUS list. Differences in distributions were exam-
ined using chi2-test. T-test for unpaired samples was
conducted to examine differences of means between differ-
ent groups. A logistic regression was conducted to identify
predictors for PIM-prescription.
The procedure of qualitative content analysis of inter-
views with FPs [2] is based on Mayring [25]. Two re-
searchers analyzed the interview manuscripts by using
MAXQDA® software to categorize contextual factors and
individual reasons for PIM prescription from FPs’ point of
view. The contents of the interviews were classified induct-
ively to indicate pertinent categories. The derived categor-
ies were discussed and consented in the research team.
All data were pseudonymously recorded and analyzed.
For integrating results, interview data (e.g. reported mo-
tives of prescription) were triangulated with data based
on patient records’ analysis (e.g. relative frequencies of
PIM prescription).
Results
Description of participating family physicians
Out of 33 academic teaching physicians of the Depart-
ment of General Practice of TU Dresden, working in
Dresden, 7 (of which 5 were female) participated in this
study. The age of the participants was distributed be-
tween 43 and 61 years, and professional experiences
were reported between 7 and 22 years. Out of 7 FPs, 3
worked at group practices and 4 at single practices, At
the FPs’ practices, between 2 and 6 medical assistants
were employed.
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Table 1 Description of case vignettes regarding documented prescription of PIM
FP Documented chronic
conditions of the case
(ICD-10)
Documented acute
diagnosis of the case
(ICD-10)
Prescription of PIM per
quarter: agents/amount
(prescribed daily dosage)
Further agents for long-term treatment/
same quarter
FP1 D25: Leiomyoma of uterus F43: Reaction to severe
stress, and adjustment
disorders
Zolpidem/80 pellets
(missing)
Candesartan, Carbamazepine, Doxepin,
Gabapentin, Metoprolol, Metformin,
PravastatinE22: Hyperfunction of
pituitary gland
E78: Disorders of lipoprotein
metabolism
G25: Other extrapyramidal
and movement disorders
G47: Sleep disorders
G56: Mononeuropathies of
upper limb
G58: Other
mononeuropathies
I10: Essential (primary)
hypertension
I65: Occlusion and stenosis of
precerebral arteries
R55: Syncope and collapse
FP2 F13: Mental and behavioral
disorders due to use of
sedatives or hypnotics
M54: Dorsalgia Zopiclone/60 pellets
(7.5 mg/day), Lorazepam/
missing (2.5 mg/day)
Acetylsalicylic acid, Amlodipine, Calcitrol,
Carvedilol, Cholecalciferol, Minoxidil,
Mirtazapine, Pantoprazole, Torasemide,
Valsartan
F34: Persistent mood
[affective] disorders
F40: Phobic anxiety disorders
G47: Sleep disorders
I10: Essential (primary)
hypertension
N18: Chronic kidney disease
T88: Other complications of
surgical and medical care, not
elsewhere classified
FP3 E03: Hypothyroidism J06: Acute upper
respiratory infections of
multiple and unspecified
sites
Zolpidem/80 pellets
(10 mg/day)
Beclomethasone, Bisoprolol, Cobalamin,
Duloxetine, Hydrochlorothiazide,
Lactulose, Levothyroxine, Metoclopramide,
Omeprazole, Salbutamol, Tramadol,
E53: Deficiency of other B
group vitamins
I35: Nonrheumatic aortic
valve disorders I50: Heart
failure
K29: Gastritis and duodenitis
M48: Other spondylopathies
Q61: Cystic kidney disease
R15: Faecal incontinence
R52: Pain, not elsewhere
classified
FP4 D86: Sarcoidosis none Zolpidem/100 pellets
(10 mg/day)
Hydrochlorothiazide, Naloxone,
Nitrendipine, Pregabalin, Tilidine, Valsartan
E78: Disorders of lipoprotein
metabolism and other
lipidaemias
G47: Sleep disorders
H53: Visual disturbances
I10: Essential (primary)
hypertension
Voigt et al. BMC Family Practice  (2016) 17:93 Page 4 of 11
Of all the 7 FPs’ patients a number of 2826 met the inclu-
sion criteria (≥2 chronic conditions and ≥ 2 related long-
term medication), and 1846 patients (65.3 %) gave their
consent for participation in the study. The number of par-
ticipating patients per FP varied between a minimum of
120 and a maximum of 455. 55 % were females, and the
age distribution was between 23 and 100 years with a mean
age of 69 (±11 SD) years. 69.4 % of the patients were >
65 years old who will be in focus of following analysis.
Based on the small sample of participating FPs, the re-
sults of the study are limited regarding representative-
ness of FPs and patients. To check for potential biases
we compared our data with results of comparable stud-
ies (external validation, see below).
Description of the sample: elderly patients
Elderly patients [n = 1241, mean age: 76 (±6 SD), fe-
males: 56.6 %] were characterized in average by 8.3
Table 1 Description of case vignettes regarding documented prescription of PIM (Continued)
I83: Varicose veins of lower
extremities
M25: Other joint disorders,
not elsewhere classified
M81: Osteoporosis without
pathological fracture
N17: Acute renal failure
R26: Abnormalities of gait
and mobility
Z93: Artificial opening status
FP5 C80: Malignant neoplasm,
without specification of site
R07: Pain in throat and
chest
Zopiclone/missing (7.5 mg/
day)
Bisoprolol, Hydrochlorothiazide, Ramipril,
Trimipramine, Pantoprazole, Acetylsali-cylic
acid, Ibuprofen
H53: Visual disturbances
I10: Essential (primary)
hypertension
I27: Other pulmonary heart
diseases
I34: Atrial fibrillation and
flutter
K43: Ventral hernia
R26: Abnormalities of gait
and mobility
Z93: Artificial opening status
Z96: Presence of other
functional implants
FP6 E11: Type 2 diabetes mellitus none Zopiclon/120 pellets
(missing)
Allopurinol, Amlodipine, Enalapril,
Moxonidine
I10: Essential (primary)
hypertension
I50: Heart failure
M10: Gout
N08: Glomerular disorders in
diseases classified elsewhere
N18: Chronic kidney disease
FP7 E78: Disorders of lipoprotein
metabolism and other
lipidaemias
M54: Dorsalgia Zopiclon/180 pellets
(7.5 mg/day)
Allopurinol, Felodipine, Metoprolol,
Olmesartan
E79: Disorders of purine and
pyrimidine metabolism
F51: Nonorganic sleep
disorders I10: Essential
(primary) hypertension
J44: Other chronic obstructive
pulmonary disease
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[(±3.7 SD] documented chronic diagnosis (ICD 10) that
include a total of 543 different ICD-Codes (shortened to
first figure).
Most prevalent diagnosis described typical medical con-
ditions of the metabolic syndrome: for 84.0 % of patients >
65 years essential hypertension (I10), for 49.3 % lipometa-
bolic disorders (E78) and for 39.3 % diabetes mellitus 2
(E11) was documented (see Table 2). In 16.1 % of cases
there was a co-occurrence of these three diagnoses as a
hint for prevalence of a metabolic syndrome.
65.5 % of the elderly patients were given 4 and more
drugs in long term medications (M: 6.3 ± 3.3 SD). The
number of prescribed drugs correlated not very strongly
with the number of chronic diagnosis (r = 0.34/p ≤ 0.001).
Regarding the interpretation of documented chronic
diagnoses the limitation of validity based on missing or
unspecific diagnoses needs to be considered. Patients’ re-
cords consist on information about chronic diagnoses
documented primary for billing purposes. Although billed
drugs and medical services need to be confirmed by docu-
menting associated diagnoses, mismatches were found in
our data. An exemplary analysis regarding congruence of
prescriptions of thyroid medications and associated thy-
roid diagnosis showed insufficiently documented thyroid
diagnosis in 26.8 % of patients with diagnosed or treated
thyroid diseases [26].
Prescription of potentially inappropriate medication
Out of the 83 PIM in the German PRISCUS list (includ-
ing inappropriate drugs and in some cases inadequately
dosed drugs), 41 PIM were prescribed in our sample.
Using the method of record analysis, our data include all
of FPs’ documented drug prescriptions, incl. private pre-
scriptions that are not covered by the statutory health
insurance respectively over the counter medication.
Prescriptions by specialists were only included if FP had
been informed and documented it. Since our data are re-
lated to FP prescription, the real PIM-prescription in
general will be underestimated.
To summarize, 23.9 % of elderly patients received at
least one PIM prescription, which is comparable to other
studies reporting PIM prescription rates between 22.5
and 28.4 % of elderly patients in the primary care setting
[17, 18]. 21.5 % of patients in our study got at least one
PIM as medication for chronic conditions and 3.1 % to
care for acute symptoms. Sedatives and hypnotics were
the most frequent (13.7 %) prescribed PIM-drugs in pa-
tients > 65 years (see Fig. 1).
Zopiclon (4.3 %), Zolpidem (2.3 %), Diazepam and Dox-
acosin (each 1.9 %) were the top-3-PIM in our sample (see
Table 3). This is different to results of Zimmermann et al.
(2013) who showed highest rate of PIM prescription in
the agent group of antidepressants [18]. Since antidepres-
sants and sedatives/hypnotics as most described PIM are
commonly given for mental disorders, we examined the
proportion of patients with one (or more) related diagno-
se(s) in our sample. 20.5 % of all patients > 65 years suf-
fered from at least one documented mental disorder
(ICD-10, chapter F). Based on this, the differences be-
tween our and Zimmermann’s data, concerning the high-
est rate of PIM prescriptions (as described above), could
be explained by the difference in prevalence of depression:
whereas 9.4 % of all patients in our sample suffered a doc-
umented form of depression, in Zimmermann’s sample
there were 12.2 % cases of depression at base line, age-
related increasing to > 20 % in the follow-ups [18].
A significantly higher number of female (F: 27.6 % vs.
M: 19.1 %, χ2 = 12.0/p ≤ 0.001) and very old patients
(≥80 years: 31.3 % vs. < 80 years: 21.6 %, χ2 = 11.7/p ≤
0.001) received a PIM prescription. Patients with at least
Table 2 Top Ten of documented chronic and acute diagnosis in patients > 65 years (n = 1241)
Chronic diagnosis Absolute
frequency
Relative
frequency
Acute diagnosis Absolute
frequency
Relative
frequency
I10 Essential hypertension 1076 84.0 M54 Dorsalgia 38 5.4
E78 Dyslipidemia 632 49.3 J06 Acute upper respiratory infections 35 5.0
E11 Diabetes mellitus type 2 503 39.3 N39 Other disorders of urinary system 23 3.3
I25 Chronic ischaemic heart disease 422 32.9 R10 Abdominal and pelvic pain 22 3.1
M81 Osteoporosis 209 16.3 R21 Rash and other nonspecific skin
eruption
22 3.1
I83 Varicosis of lower extremities 193 15.1 M53 Other dorsopathies, not elsewhere
classified
21 3.0
I48 Atrial flutter/fibrillation 193 15.1 F43 Reaction to severe stress 21 3.0
Z92 long-term (current) use of
anticoagulants
183 14.3 M25 Other joint disorders, not
elsewhere classified
19 2.7
M17 Gonarthrosis 182 14.2 G47 Sleep disorders 15 2.1
E79 Disorders of purine and pyrimidine
metabolism
163 12.7 F32 Depressive episode 14 2.0
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one PIM prescription were characterized by a signifi-
cantly higher number of chronic diagnoses (M 9.3 ± 3.9
SD) and long-term medication (7.5 ± 3.7 SD) compared
to patients without a PIM prescription (8.0 ± 3.6 SD/t-
test: p ≤ 0.001 respectively 5.4 ± 3.0 SD, t-test: p ≤ 0.001).
Influencing factors on prescription of PIM
Conducting a logistic regression, we examined the influence
of binary associated factors on prescription of PIM in a
multivariate model. Including gender, age, documented
diagnose of a mental disorder (ICD-10: F), number of diag-
noses and number of long-term medication in the regres-
sion model, the strongest effect was detected for
documented mental disorders (Exp(B) = 2.0/p ≤ 0.001),
followed by female gender (Exp(B) = 1.6/p ≤ 0.01) and num-
ber of long-term medication (Exp(B) = 1.2/p ≤ 0.001) as pre-
dictors for the probability of a PIM prescription. Age and
number of diagnoses were not predictive for PIM
prescription. The three mentioned predictors explained just
14.9 % of the variance (Nagelkerkes R2 = 0.149) of the
dependent variable. However, there will be other influen-
cing variables we did not include in the model. Our find-
ings are comparable to other studies that found depression
as one of the common mental disorders in elderly patients
as main predictor (OR = 2.42) for PIM prescription,
followed by the number of prescribed drugs (OR = 1.99)
[18]. A positive correlation between the number of pre-
scribed drugs and the risk of PIM in the elderly was also
shown in the study of Schubert [19].
Knowledge and application of PRISCUS-list
PRISCUS was generally known by 5 of 7 interviewed FPs,
but the application of the list in daily practice diverged be-
tween the interviewees. Several FPs reported its use in
daily practice as an instrument for orientation. Others de-
nied or refused to use the list using different arguments
pro and contra PRISCUS (see Table 4). Skeptical argu-
ments regarding applicability in daily practice and its ben-
efits for individual patients within the complex context of
multimorbidity were reported commonly:
Yes, both me and my colleagues have a short version
pinned up at our desks. But if you look at the list you
get lost even before the consultation with the patient
starts. It is not useful at all, unless you want to refuse
a prescription of a medication, of course. [FP6]
The inherent problem of lack of time (the average dur-
ation of consultation at FPs’ practices is ca. 8 min per pa-
tient in Germany [27]) was mentioned by most of the FPs.
This finding is comparable to other studies that also
pointed out lack of time as a main barrier for appropriate
prescribing [20, 21] or for implementing recommenda-
tions of guidelines in daily practice [28].
Fig. 1 Frequencies of prescribed PIMs summarized in agents groups in elderly patients (n = 1241)
Table 3 Top Ten of the prescribed PIM in elderly patients >
65 years (n = 1241)
Range Agent Total
frequency
Total
frequency (%)
1 Zopiclone (>3.75 mg/d) 53 4.3
2 Zolpidem (>5 mg/d) 29 2.3
3 Diazepam 24 1.9
Doxazosin 24 1.9
4 Nifedipine 23 1.9
5 Etoricoxib 18 1.5
6 Medazepam 17 1.4
7 Lorazepam (>2 mg/d) 16 1.3
8 Brotizolam (>0.125 mg/d) 15 1.2
9 Amitryptiline 13 1.1
Nitrazepam 13 1.1
10 Indomethacin 10 1.0
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Several FPs were doubtful regarding the evidence of
PRISCUS list since most of pharmacological studies ex-
clude elderly patients, and therefore related evidence is
missing. Other studies also showed partly existing
skeptical attitudes of physicians regarding cited evidence
in guidelines [29]. Two FPs criticized that the PRISCUS
list does not recommend “practicable and pharmaco-
logically based alternatives” [FP6]. For instance, regard-
ing the prescription of sedatives/hypnotics, FPs reported
great uncertainty (see below).
One FP argued that primary care physicians mostly act
intuition- and experience-based. From his point of view,
evidence-based practice that includes implementation of
guidelines in daily practice would not be typical for FPs’
practice. Triangulating these interview data with related
data of patient records’ analysis, we detected that this in-
tuition- and experience-oriented FP had a visibly lower
prescription rate of PIM while reporting the highest pro-
portion of patients > 65 years. Nevertheless, this single
example might not be representative for all FPs. How-
ever, intuition-based and evidence-based acting do not
exclude each other in the dichotomous way of a “zero-
sum relationship” [30].
Social desirability was assumed in some FPs who re-
ported knowing PRISCUS. Asked for their concrete criti-
cisms they first reported weakness of PRISCUS list in
general, and, after repeating the question, they apologized
for not remembering since they do not use the list. There
were two FPs knowing nothing of PRISCUS and PIM at
all. This is similar to results of other studies describing
educational lacks in primary care as well as hospital physi-
cians, regarding appropriate prescribing in elderly patients
[20, 21].
Reported causes for prescription of potentially
inappropriate medication
Most reported cause for PIM prescription was the state-
ment of unavoidability of PIM because having no alter-
natives in medication, especially in multimorbid
patients. FPs prescribing PIM appreciated the related
higher risk for unexpected medication-related events
and reported to re-consult these patients in shorter
periods.
Regarding polypharmacy, there are no convincing
recommendations as to what to prescribe as an
alternative. Full stop. That is why I consult these
patients (note: with PIM) closely. I will see them
several times in the quarter at my practice to keep a
close eye on them. [FP2]
(Note: As with PIM) you have similar issues with these
huge amounts of pain pellets or patients receiving
Falithrom (note: Phenprocoumon). Every time
something can happen. But this is unavoidable, isn’t
it? [FP5]
Further arguments are related to FPs’ prioritization re-
garding therapeutic objectives. There are stronger
patient-related factors than age that influence their deci-
sion of a certain medication. Based on this, the PIM-
topic could become less important:
If you keep the wellbeing of the patient as the primary
goal in mind, then a lot will be sorted based on this
prioritization. Age seems to be a difficult criterion in
general, so patients’ health status and perspectives
should be more important. [FP2]
Regarding sedatives, benzodiazepine vs. z-drugs it is
like being caught between a rock and a hard place.
I am certain that it (note: PIM) is not recom-
mended by PRISCUS but there are no alternatives.
And the patient needs to get sleep and be pain-free
from time to time. So we talk to the patient about
the medication, how to limit it time-wise and how
to monitor it closely. [FP1]
Table 4 Pros and Cons of the PRISCUS-list from FPs’ point of
view
FPs’ arguments pro PRISCUS FPs’ arguments contra PRISCUS
• Includes no-go-medication you
have to remember every time
Not practicable in FPs’ daily practice
since
• Good for orientation • does often not fit individual
patients’ needs
• Possible argument if FP
wants to refuse a medication
• within its complex context of
multimorbidity
• does not recommend practicable
and pharmacologically based
alternatives
• does not fit experience-based
practice
• does not fit patient demands for a
certain PIM based on individual
positive experiences
• limited time in consultations a) to
check additional recommendation
lists and b) to convince patients for
new medication
• chronological age does not match
biological age: lot of patients >
65 years have a younger biological
age
• mistrust in PRISCUS based on
missing evidence for medication of
multimorbid elderly patients
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Own bad experiences regarding a) change of medica-
tion to avoid PIM and b) refusal of following prescrip-
tion of sedatives/hypnotics (that also belong to PIM if
certain dosage is reached) to addicted patients resulted
in a kind of resignation.
You can start making changes in medication, yes, but
most of them are not successful. [FP1]
In context of FPs’ care for patients who are addicted to
hypnotics, PIM-topic seemed to become subordinated
whereas treatment of addiction got into the main focus:
Well, you can speak like a priest in the church: if
patients have a certain level of addiction it is really
difficult. I could refuse them the medication, but then
they will go to a different [physician], so this doesn’t
make any sense. [FP7]
This finding is convenient to our previous result of the
logistic regression (see above), showing that a docu-
mented mental disorder was the strongest predictor for
prescription of PIM.
Most of the interviewed FPs described the advantages
of caring primarily for patients addicted to hypnotics be-
cause getting them under control in “one hand”. But fi-
nally they seem to be still perplexed:
I had special cases of patients, when I said, okay, let’s
keep them in “one hand” and see if we can somehow
take responsibility for it. Yes, we try to care for them
individually. Last time I had a patient, she picked up
sleeping pills from her neurologist, from me and from
another GP. And then at night she had a bad fall
because she was just completely in the swash. Finally
she was hospitalized, but how to manage her? I have
no magic remedy for this problem. [FP4]
Most of the FPs described the importance of close co-
operation with neurologists/psychiatrists regarding care
for patients addicted to hypnotics, but several problems
were pointed out. First, they reported patients’ difficul-
ties to get access to a psychiatrist for “just” sleeping dis-
orders and second, they reported communication lacks
regarding prescriptions of medications and lacks in re-
ferral of clinical information. And third, some of the FPs
pointed out an uncritical prescribing by psychiatrists
without looking at the patient in their entirety including
existing multimorbidity. But especially in the case of
out-patient detoxification, FPs underlined the necessity
of cooperation. To summarize, most of the FPs saw great
challenges and chances in a better cooperation with psy-
chiatrists to improve medical care for (elderly) patients
addicted to hypnotics.
Conclusion
This is to our best knowledge the first published study tri-
angulating PIM prescription data based on the analysis of
patients’ records with qualitative interview data regarding
case-related motives of PIM prescription. In summary,
prescription of PIM was mainly a topic of chronic disease
treatment. We find out that it is essential to see FPs in a
complex decision making situation with several influen-
cing factors on their prescribing, including:
1) patient-oriented prioritization reflecting i.e.
multimorbidity and related polypharmacy, existing
mental disorders, gender, patients’ requests [29] and
experiences
2) FPs’ experiences in daily practice [29] regarding e.g.
(inter) actions of drugs [31], reactions of patients in
case of refusal or change of a drug
3) FPs’ knowledge regarding e.g. existing evidence/
recommendations and their trust in it
4) dependent on quality of cooperation with in- and
out-patient specialist; forwarded information regard-
ing clinical indication and prescribed drugs
5) organizational characteristics, i.e. lack of time in
daily practice, follow-up prescriptions of PIM ini-
tially prescribed by specialists.
Obviously, there is a problem with the applicability of
guidelines and recommendations, rooted in the special
characteristics of FPs´ work: the individual consideration
of decisions against the background of the knowledge of
the patient’s medical history, patient´s characteristics
and suspected adherence.
Partly, FPs reported to be not really convinced of their
decisions foreseeing associated higher risks of drug related
adverse events. Assuming that they will not find medication
alternatives for individual multimorbid patients, frequently
re-consultations and laboratory tests were seen as methods
to detect drug related problems as soon as possible.
The partly detected education lack regarding PIM and
PRISCUS shows challenges for further educational tasks
that should take the partly missing trust in recommen-
dation and PRISCUS into account even though influence
of new guidelines and their recommendations on physi-
cians’ daily practice seems to be limited [29].
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